Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last CNY57.44 CNY
Change Today +1.52 / 2.72%
Volume 12.6M
002038 On Other Exchanges
Symbol
Exchange
Shenzhen
As of 3:00 AM 04/27/15 All times are local (Market data is delayed by at least 15 minutes).

beijing sl pharmaceutical -a (002038) Snapshot

Open
CNY56.00
Previous Close
CNY55.92
Day High
CNY58.68
Day Low
CNY56.00
52 Week High
04/14/15 - CNY59.99
52 Week Low
12/30/14 - CNY38.51
Market Cap
26.2B
Average Volume 10 Days
10.2M
EPS TTM
CNY1.54
Shares Outstanding
456.8M
EX-Date
07/4/14
P/E TM
37.3x
Dividend
CNY0.20
Dividend Yield
0.35%
Current Stock Chart for BEIJING SL PHARMACEUTICAL -A (002038)

Related News

No related news articles were found.

beijing sl pharmaceutical -a (002038) Related Businessweek News

No Related Businessweek News Found

beijing sl pharmaceutical -a (002038) Details

Beijing SL Pharmaceutical Co., Ltd., a biotechnology-pharmaceutical company, develops and markets gene engineering drugs for human health. Its principal products include Li Sheng Su, a recombinant human granulocyte colony-stimulating factor for injection; Mai Ge Er, a recombinant human interleukin-11 for injection; and Xin Ji Er, a recombinant human 125Ala interleukin-2 for injection. The company also offers Fu Ji Fu, a lyophilized recombinant human basic fibroblast growth factor for external use. In addition, it provides products for oncology, organ transplantation, cardiovascular, wound management, liver diseases, as well as APIs. The company was formerly known as Beijing BaiLuyuan Bio-Pharmaceutical Co., Ltd and changed its name to Beijing SL Pharmaceutical Co., Ltd. in 1998. The company was founded in 1994 and is based in Beijing, the People’s Republic of China.

Founded in 1994

beijing sl pharmaceutical -a (002038) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

beijing sl pharmaceutical -a (002038) Key Developments

Beijing SL Pharmaceutical Co., Ltd. Proposes Amendments to Articles of Association

Beijing SL Pharmaceutical Co., Ltd. will hold the first extraordinary general meeting of 2015 on January 08, 2015 to consider amendments to the company's articles of association.

Beijing SL Pharmaceutical Co., Ltd., Special/Extraordinary Shareholders Meeting, Jan 08, 2015

Beijing SL Pharmaceutical Co., Ltd., Special/Extraordinary Shareholders Meeting, Jan 08, 2015., at 14:00 China Standard Time. Agenda: To consider change of directors and independent directors, accumulative voting system applicable; to consider amendments to the Company's rules of procedures governing shareholders' general meetings; to consider guarantee for the bank credit of a wholly-owned subsidiary; and to consider amendments to the company's articles of association.

Beijing SL Pharmaceutical Co., Ltd. to Report Q3, 2014 Results on Oct 24, 2014

Beijing SL Pharmaceutical Co., Ltd. announced that they will report Q3, 2014 results on Oct 24, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
002038:CH CNY57.44 CNY +1.52

002038 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 002038.
View Industry Companies
 

Industry Analysis

002038

Industry Average

Valuation 002038 Industry Range
Price/Earnings 36.9x
Price/Sales 20.6x
Price/Book 8.5x
Price/Cash Flow 36.9x
TEV/Sales 19.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BEIJING SL PHARMACEUTICAL -A, please visit www.slpharm.com.cn. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.